Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles

被引:93
作者
Tang, Jing [1 ,2 ]
Aittokallio, Tero [1 ]
机构
[1] Univ Helsinki, Inst Mol Med Finland, FIMM, FI-00290 Helsinki, Finland
[2] VTT Tech Res Ctr Finland, FI-02044 Espoo, Finland
基金
芬兰科学院;
关键词
Network pharmacology; computational models; experimental design; anticancer therapies; SYNERGISTIC DRUG-COMBINATIONS; TARGET INTERACTION NETWORKS; IN-VITRO; CELLULAR TARGETS; SYSTEMS PHARMACOLOGY; SIGNALING NETWORKS; DISCOVERY; CANCER; PREDICTION; IDENTIFICATION;
D O I
10.2174/13816128113199990470
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Polypharmacology has emerged as novel means in drug discovery for improving treatment response in clinical use. However, to really capitalize on the polypharmacological effects of drugs, there is a critical need to better model and understand how the complex interactions between drugs and their cellular targets contribute to drug efficacy and possible side effects. Network graphs provide a convenient modeling framework for dealing with the fact that most drugs act on cellular systems through targeting multiple proteins both through on-target and off-target binding. Network pharmacology models aim at addressing questions such as how and where in the disease network should one target to inhibit disease phenotypes, such as cancer growth, ideally leading to therapies that are less vulnerable to drug resistance and side effects by means of attacking the disease network at the systems level through synergistic and synthetic lethal interactions. Since the exponentially increasing number of potential drug target combinations makes pure experimental approach quickly unfeasible, this review depicts a number of computational models and algorithms that can effectively reduce the search space for determining the most promising combinations for experimental evaluation. Such computational-experimental strategies are geared toward realizing the full potential of multi-target treatments in different disease phenotypes. Our specific focus is on system-level network approaches to polypharmacology designs in anticancer drug discovery, where we give representative examples of how network-centric modeling may offer systematic strategies toward better understanding and even predicting the phenotypic responses to multi-target therapies.
引用
收藏
页码:23 / 36
页数:14
相关论文
共 177 条
  • [21] Use of structure Activity data to compare structure-based clustering methods and descriptors for use in compound selection
    Brown, RD
    Martin, YC
    [J]. JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1996, 36 (03): : 572 - 584
  • [22] An intuitive look at the relationship of Ki and IC50:: A more general use for the Dixon plot
    Burlingham, BT
    Widlanski, TS
    [J]. JOURNAL OF CHEMICAL EDUCATION, 2003, 80 (02) : 214 - 218
  • [23] Using genome-wide transcriptional profiling to elucidate small-molecule mechanism
    Butcher, RA
    Schreiber, SL
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2005, 9 (01) : 25 - 30
  • [24] Search Algorithms as a Framework for the Optimization of Drug Combinations
    Calzolari, Diego
    Bruschi, Stefania
    Coquin, Laurence
    Schofield, Jennifer
    Feala, Jacob D.
    Reed, John C.
    McCulloch, Andrew D.
    Paternostro, Giovanni
    [J]. PLOS COMPUTATIONAL BIOLOGY, 2008, 4 (12)
  • [25] Drug target identification using side-effect similarity
    Campillos, Monica
    Kuhn, Michael
    Gavin, Anne-Claude
    Jensen, Lars Juhl
    Bork, Peer
    [J]. SCIENCE, 2008, 321 (5886) : 263 - 266
  • [26] MINT, the molecular interaction database: 2009 update
    Ceol, Arnaud
    Aryamontri, Andrew Chatr
    Licata, Luana
    Peluso, Daniele
    Briganti, Leonardo
    Perfetto, Livia
    Castagnoli, Luisa
    Cesareni, Gianni
    [J]. NUCLEIC ACIDS RESEARCH, 2010, 38 : D532 - D539
  • [27] Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model
    Chang, Roger L.
    Xie, Li
    Xie, Lei
    Bourne, Philip E.
    Palsson, Bernhard O.
    [J]. PLOS COMPUTATIONAL BIOLOGY, 2010, 6 (09)
  • [28] Comparing bioassay response and similarity ensemble approaches to probing protein pharmacology
    Chen, Bin
    McConnell, Kevin J.
    Wale, Nikil
    Wild, David J.
    Gifford, Eric M.
    [J]. BIOINFORMATICS, 2011, 27 (21) : 3044 - 3049
  • [29] Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data
    Chen, Bin
    Dong, Xiao
    Jiao, Dazhi
    Wang, Huijun
    Zhu, Qian
    Ding, Ying
    Wild, David J.
    [J]. BMC BIOINFORMATICS, 2010, 11
  • [30] Structure-based maximal affinity model predicts small-molecule druggability
    Cheng, Alan C.
    Coleman, Ryan G.
    Smyth, Kathleen T.
    Cao, Qing
    Soulard, Patricia
    Caffrey, Daniel R.
    Salzberg, Anna C.
    Huang, Enoch S.
    [J]. NATURE BIOTECHNOLOGY, 2007, 25 (01) : 71 - 75